PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026
PROCEPT BioRobotics (Nasdaq: PRCT) announced that members of its management team will present and host investor meetings at the Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PROCEPT BioRobotics (Nasdaq: PRCT) announced that members of its management team will present and host investor meetings at the Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15, 2026. Investors can view the presentation or request meetings through their Baird representative.
Details
News Market Reaction – PRCT
On Aug 17, the day this news came out, PRCT closed 2.59% below the previous close.
Data tracked by StockTitan Argus for the Aug 17 session.
Key Figures
- Conference date
- September 15, 2026
- Baird 2026 Global Healthcare Conference
Historical Context
-
Revenue growth, reiterated guidance, and improved gross margin accompanied quarterly results.
-
The company scheduled release of second-quarter financial results and its conference call.
-
WATER IV RP enrollment was completed and expanded FDA IDE approval was announced.
-
Updated AUA guidelines strengthened recommendations for Aquablation therapy.
-
Management announced participation in three upcoming investor conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced members of management will present and host investor meetings at the upcoming Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15.
To view the presentation or schedule a meeting with management, please reach out to your Baird representative.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The Company manufactures the AQUABEAM® and HYDROS® Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. In addition to its leadership in BPH treatment, the Company is pursuing clinical research initiatives in prostate cancer utilizing investigational applications of its robotic and AI-enabled technologies. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Investor Contact:
Marissa Bych
Managing Director
Gilmartin Group LLC
Marissa@gilmartinir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.